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Background: Nontypeable Haemophilus influenzae (NTHi) is a significant human pathogen responsible for
respiratory tract infections and the most common cause of recurrent otitis media. Type II toxin-antitoxin (TA)
systems are genetic elements that code for a stable protein toxin and a labile antitoxin that are thought to be
involved in metabolic regulation of bacteria by enabling a switch to a dormant state under stress conditions. The
contribution to infection persistence of the NTHi TA loci vapBC-1 and vapXD was examined in this study.
Results: Deletions in vapBC-1, vapXD and vapBC-1 vapXD significantly decreased the survival of NTHi co-cultured
with primary human respiratory tissue at the air-liquid interface and in the chinchilla model of otitis media. The TA
deletions did not affect the growth dynamics of the mutants in rich media, their ultra-structural morphology, or
display appreciable synergy during NTHi infections. The toxin and antitoxin proteins of both pairs heterodimerized
in vivo. Consistent with our previous findings regarding the VapC-1 toxin, the NTHi VapD toxin also displayed
ribonuclease activity.
Conclusions: We conclude that the vapBC-1 and vapXD TA loci enhance NTHi survival and virulence during
infection in vitro and in vivo using a mechanism of mRNA cleavage, and that these conserved TA pairs represent
new targets for the prophylaxis and therapy of otitis media and other NTHi-caused mucosal diseases.
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Nontypeable Haemophilus influenzae (NTHi) is a Gram-
negative organism that is both a common commensal of
the upper respiratory tract as well as a significant cause
of respiratory tract infections in humans. NTHi is the
second most common cause of acute otitis media after
Streptococcus pneumoniae and, in many studies, is the
most common cause of recurrent otitis media based on
cultures of middle ear fluids obtained by tympanocen-
tesis [1]. Recurrent otitis media is associated with pain,
the need for insertion of tympanostomy tubes under
general anesthesia, conductive hearing impairment, and
delayed speech and language development [2]. Currently,
otitis media is commonly treated with antibiotics, among
which amoxicillin is the consensus recommendation for* Correspondence: ddaines@odu.edu
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reproduction in any medium, provided the orthe initial therapy [3,4]. But approximately 20–35% of
NTHi strains, depending on geographic location, produce
β-lactamase and these strains are resistant to amoxicillin
[4]. Moreover, there is currently no licensed vaccine avai-
lable to prevent NTHi infections. Thus, illuminating the
molecular mechanisms of NTHi infections could lead to
the development of novel strategies to improve prophy-
laxis and treatment of otitis media.
Adhesin molecules on the surface of NTHi are shown
to bind to respiratory tract target cells and activate these
cells to induce inflammation [5,6]. NTHi also pene-
trates into human respiratory tract cells (epithelial cells and
macrophages) and the interstitium to cause nasopharyngeal
colonization and respiratory infection [7-10]. Biofilms of
NTHi found in middle ears are postulated to be responsible
for the resistance to clearance by host immune responses
and antibiotic treatments, therefore resulting in recurrent
otitis media [5,6,11,12]. However, there is controversy
whether the reported biofilm is an outcome of infectious. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phenotype of NTHi virulence [13]. Although these ob-
servations have advanced our understanding, much of the
pathogenesis of NTHi-induced otitis media, especially re-
current otitis media, is largely unknown.
Toxin-antitoxin (TA) systems are small genetic mo-
dules comprised of two components, a stable toxin and
its labile antitoxin. TA systems in prokaryotic genomes
are classified into 3 types, based on the antitoxin nature
and mode of action. While toxins are always proteins,
antitoxins are either RNAs (types I and III) or proteins
(type II) [14]. Several common families of type II mod-
ules have been identified on the chromosomes of bac-
teria and archaea: relBE, higBA, mazEF, ccdAB, vapBC,
parDE, phd–doc, ζε, hipBA, and yoeB–yefM [15]. Type II
TA systems are thought to be part of the mobilome and
to move from one genome to another through horizon-
tal gene transfer [16,17]. They are hypothesized to func-
tion in stress management either by promoting altruistic
sacrifice of a large fraction of the population (the pro-
grammed cell death hypothesis, PCD) or by inducing a
dormant stage (bacteriostasis) that allows cells to cope
with stress [18-20].
Type II TA systems are typically two-gene operons
with the antitoxin encoded upstream of the toxin gene.
The proteic antitoxins bind their cognate toxins and
inhibit toxin activity. Antitoxins or toxin-antitoxin com-
plexes autorepress TA module transcription. Under stress-
ful environmental conditions such as nutrient limitation,
antibiotic therapy, or oxidative stress, TA modules are
activated. The labile antitoxin is degraded by either the
Lon or Clp proteases and the more stable toxin is freed to
facilitate growth arrest. Many toxins are mRNA-specific
RNases that rapidly inhibit protein synthesis, inducing
a bacteriostatic state. Upon improved conditions (or re-
moval of stress), antitoxin synthesis resumes to counteract
toxin activity, and tmRNA activity rescues ribosomes
arrested on toxin-cleaved messages [21,22]. Virulence-
associated protein (vap) genes, first identified in pathogenic
strains of the Gram-negative, strict anaerobe Dichelobacter
nodosus, are found as transmissible genetic elements for
the transfer of virulence determinants [23]. The vap genes
are recognized as a part of pathogenicity islands (PAI), a
group of laterally-transferred genes in the bacterial gen-
ome, which help the organism explore and adapt to new
ecological niches [24,25].
Four vap operons, toxAvapA, vapBC-1, vapBC-2, and
vapXD have been identified in the genomes of numerous
NTHi strains, including Rd KW20 [26], R2866 [27], and
86-028NP [28]. All vap operons display the characteristic
features of type II TA modules, and vapBC-1 and vapXD
have been shown to act as TA loci in NTHi [29,30]. Du-
ring recurrent and chronic otitis media, NTHi are exposed
to hostile conditions such as antibiotic treatment, hostimmune responses, and nutrient deprivation. It is thought
that a subpopulation of NTHi can resume the infection
after cessation of these stressors, resulting in a persistent
infection. Although TA modules function to allow bacter-
ial adaptation to environmental stresses, the pathogenic
roles of the NTHi vapBC-1 and vapXD operons have not
been elucidated in otitis media. It has been shown that the
protein products of canonical type II TA loci interact to
form protein complexes that autoregulate their cognate
promoters [22]. Accordingly, we examined the heterodi-
merization characteristics of the VapB-1 antitoxin with the
VapC-1 toxin, as well as interactions of the antitoxin VapX
with the toxin VapD. We then constructed vapBC-1,
vapXD, and vapBC-1 vapXD double deletion mutants in
strain 86-028NP. The survival properties of these mutants
were compared to the wild type parent strain during long-
term infections of a primary human respiratory epithelial
tissue at the air-liquid interface (ALI), the EpiAirway™ tis-
sue. The NTHi TA mutants were then analyzed for per-
sistence in vivo using the chinchilla model of otitis media
over the course of a 4-day infection. Finally, we tested the
VapD toxin for ribonuclease activity in vitro. The current
work is aimed at uncovering the contributions of vapBC-1
and vapXD to NTHi-caused otitis media, which could
lead to new vaccine or pharmaceutical targets for the
prophylaxis and therapy of this disease.
Results
Interactions of the Vap proteins in vivo
To detect the ability of VapB-1 and VapC-1 to form he-
terodimers in vivo, β-galactosidase activity assays were
carried out using an E. coli-based LexA protein-protein
interaction reporter system as previously described [31].
In this system, with no protein fused to the LexA DNA
binding domain (DBD) of either plasmid pSR658 or
pSR659 in strain SU202, the repressor cannot form a
dimer, and the expression of the lacZ reporter gene is
constitutive. However, a reconstituted repressor formed
by heterodimerization of fused proteins can bind to the
engineered operator region, decreasing transcription of
the reporter gene, but a homodimer, if formed, cannot
bind to the operator. Since the LexA DBD plasmids have
different copy numbers (pSR658 has a higher copy num-
ber than pSR659), we constructed reciprocal fusions and
analyzed each set as an internal control for heterodime-
rization. When we fused VapC-1 to the LexA DBD in
pSR658 (pDD859) and VapB-1 to pSR659 (pDD867), the
reporter gene expression was decreased to 458 ± 47
Miller units, whereas the unfused LexA DBD in the vec-
tors pSR658 and pSR659 allowed constitutive transcrip-
tion of the reporter gene at 1,611 ± 138 Miller units
(Figure 1). This indicated a strong protein:protein inter-
action. When the fusions were reversed, with VapB-1 in
pSR658 (pDD866) and VapC-1 in pSR659 (pDD868), the
Figure 1 VapB-1 and VapC-1 heterodimerize in vivo. 86-028NP vapB-1 or vapC-1 was fused to the LexA DNA binding domain (DBD) in the
vectors pSR658 or pSR659, resulting in pDD866 or pDD868, respectively. Reciprocally, vapC-1 or vapB-1 was also fused to the LexA DBD in the
vectors pSR658 or pSR659, resulting in pDD859 or pDD867, respectively. Each pair was co-transformed into the reporter strain SU202 and the
amount of heterodimerization was quantitated by β-galactosidase activity assays (n = 3 in triplicate). Data are expressed as mean ± SD.
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682 ± 61 Miller units. Interestingly, there was a signifi-
cant difference between the reciprocal fusions, with the
pDD859/pDD867 pair being the most efficient at repres-
sing the reporter gene.
To investigate the hetero-interactions between VapX
and VapD, the same reporter system was used as above.Figure 2 VapX and VapD heterodimerize in vivo. 86-028NP vapX or vap
pSR658 or pSR659, resulting in pDD882 or pDD884, respectively. Reciproca
pSR658 or pSR659, resulting in pDD885 or pDD883, respectively. Each pair
heterodimerization was quantitated by β-galactosidase activity assays (n = 3With VapX in pSR658 (pDD882) and VapD in pSR659
(pDD884), the reporter gene expression was decreased
to 162 ± 27 Miller units, compared to the expression in
the presence of the control vectors of 1,783 ± 85 Miller
units (Figure 2). Likewise, the reciprocal fusion, with VapD
in pSR658 (pDD885) and VapX in pSR659 (pDD883), re-
sulted in 210 ± 61 Miller units, both significantly lowerD was fused to the LexA DNA binding domain (DBD) in the vectors
lly, vapD or vapX was also fused to the LexA DBD in the vectors
was co-transformed into the reporter strain SU202 and the amount of
in triplicate). Data are expressed as mean ± SD.
Figure 3 Growth dynamics of the parent strain and vap
mutants. Strain 86-028NP and the ΔvapBC-1, ΔvapXD, and ΔvapBC-1
ΔvapXD mutants were grown in a 96 well plate at 35°C with shaking
(n = 2 in triplicate) to analyze any differences in replication. Data are
expressed as mean ± SD. No significant difference between the
growth dynamics of the various strains was observed.
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no significant difference was observed between the recipro-
cal fusions for VapX and VapD heterodimerization.
Growth dynamics of cultivated NTHi mutants
The growth behavior of the 86-028NP parent strain
and the ΔvapBC-1, ΔvapXD, and ΔvapBC-1 ΔvapXD
mutants was evaluated by culturing in sBHI for 11 h
(Figure 3). The bacterial numbers of all the strains
increased most rapidly during the first 5 hours of culture,
followed by entry into stationary phase. No significant dif-
ference in growth dynamics was observed between the
strains, demonstrating that any differences between the
survival of the wild type parent strain and the mutants inFigure 4 Ultra-structure of NTHi mutants co-cultured with EpiAirway
(A), ΔvapBC-1 (B), ΔvapXD (C), or ΔvapBC-1 ΔvapXD (D) strains at ~107 colo
were fixed and sectioned for transmission electron microscopy. No significaprimary human respiratory tissues or the chinchilla mid-
dle ear model was not attributable to a defect in replica-
tion under normal culture conditions.
Ultrastructure of NTHi mutants co-cultured with
EpiAirway tissues
To assess the effects of the TA loci on the morphologic
aspects of NTHi invasion behavior, a primary human res-
piratory epithelial tissue model at the ALI, the EpiAirway,
(MatTek, Ashland, MA USA) was used in long-term co-
culture with the various strains. Ultrastructure of the NTHi
strains was obs-erved by TEM on day 5 post-infection
(Figure 4). The 86-028NP parent strain (Figure 4A),
ΔvapBC-1 (Figure 4B), ΔvapXD (Figure 4C), and ΔvapBC-
1 ΔvapXD mutants (Figure 4D) all were found residing
both apically and within the tissues. Although NTHi are
pleomorphic by nature, the mutant organisms associated
with the tissues were intact and no significant structural
damage was observed in any of the mutant strains.
Attenuation of the vap mutants in the EpiAirway tissue
model
The EpiAirway model consists of primary, well-diffe-
rentiated tissues with tight junctions, ciliated and non-
ciliated cells, mucin-producing goblet cells, and is an
excellent in vitro representation of the human upper air-
way [32]. Indeed, the transcriptional profile of respira-
tory epithelial cells cultured at the ALI has been shown
to closely resemble that of the in vivo airway epithelium
[33]. To determine the contribution of the vapBC-1 and
vapXD TA loci to NTHi survival capability within
primary human tissues, the 86-028NP wild type, the
ΔvapBC-1, ΔvapXD, and ΔvapBC-1 ΔvapXD mutants
were co-cultured with the EpiAirway tissues and the
number of internalized (gentamicin-resistant) bacteria
for each strain was enumerated over 8 days of co-culture
(Figure 5). Although each strain was inoculated at ~107
CFU, the number of internalized wild type bacteriatissues. EpiAirway tissues were infected with the wild type
ny forming units (CFU) per insert. On day 5 after infection, the tissues
nt difference in morphology was observed for any of the mutants.
Figure 5 NTHi mutants are attenuated during long-term
co-culture in the EpiAirway tissue model. EpiAirway tissues (n = 6)
were infected with 86-028NP wild type, ΔvapBC-1, ΔvapXD, or
ΔvapBC-1 ΔvapXD mutants at ~107 colony forming units (CFU) per
insert. On days 1, 2, 4, 6, and 8 after infection, gentamicin-resistant
bacteria were harvested for CFU counts. Data are expressed as
mean ± SD.
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the ΔvapBC-1, ΔvapXD, or ΔvapBC-1 ΔvapXD mutant
strains, which showed significantly lower survival levels
over the 8 days of co-culture (n = 6, P < 0.05).
The vap mutants are attenuated in the chinchilla otitis
media model
The chinchilla model of otitis media was employed to
determine the survival of the NTHi mutants over theFigure 6 NTHi mutants are attenuated in the chinchilla otitis media m
challenge strain) were transbullarly injected with 100 μl (~ 1000 CFU) of th
mutant strain, respectively. On day 4 post-challenge, the middle ears were
as mean ± SD.course of a 4-day infection (Figure 6). After 4 days, an
average of 2.1 × 107 CFU/ml of the 86-028NP parent
strain was recovered from chinchilla middle ears. In con-
trast, the ΔvapBC-1, ΔvapXD, and ΔvapBC-1 ΔvapXD
mutants recovered from the infected middle ears were
an average of 5.1 × 105, 1.8 × 106, and 1.8 × 106 viable
CFU/ml, respectively, all significantly lower than the
wild type strain (n = 8–9 ears, P < 0.05). The ΔvapBC-1
mutant exhibited the lowest recovery numbers from the
infected middle ears among all the tested strains (n = 8
ears, P < 0.05). No significant difference between the
recovered CFU numbers was observed for the ΔvapXD
single mutant and the ΔvapBC-1 ΔvapXD double mu-
tant strain (Figure 6).The vap mutants elicited lower levels of inflammation
It has been shown that even nonviable NTHi (e.g. a
whole bacterial cell lysate) can induce an immune re-
sponse in middle ear cells in vitro and in vivo [34]. To
determine if the numbers of viable organisms recovered
from the chinchilla middle ears correlated with the in-
flammatory response, we sagittally step-sectioned middle
ears of animals infected with either the wild type pa-
rent or each of the various mutant strains. Subsequent
hematoxylin-eosin (H&E) stains of each ear were rando-
mized and blinded, then scored by one of us (A.N.W., a
Board-certified pathologist) for the extent of inflamma-
tion using a scale from 0 (no inflammation, PBS control)
to 4+ (greatest inflammatory response observed). Ex-
amples of PBS control (A, inflammatory score = 0) and
86-028NP infected (B, inflammatory score = 4+) H&E-odel. Chinchillas (4–5 animals representing 8–10 middle ears per
e 86-028NP wild type, ΔvapBC-1, ΔvapXD, or the ΔvapBC-1 ΔvapXD
washed and bacterial CFU counts were obtained. Data are expressed
Figure 7 Chinchilla middle ear sections from control and infected animals. Representative H&E stained sections from A) PBS control
(inflammatory score = 0) and B) 86-028NP-infected (inflammatory score = 4+) animals. Scale bars are 10 μm.
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Consistent with the numbers of viable bacteria reco-
vered, the middle ear sections from animals infected
with the mutant strains exhibited less inflammation on
average than the wild type parent strain (Table 1). This
suggests that the vap mutants were killed and cleared
earlier in the infection process, supporting both the role
of these TA operons in the pathogenesis of otitis media
and the importance of these modules as new therapeutic
targets.
VapD displays ribonuclease activity
We have previously shown that VapC-1 is a ribonuclease
[30]. Since the ΔvapXD mutant was also attenuated for
survival in vitro and in vivo, we assayed the purified
VapD toxin for RNase activity, and found that it was a
potent ribonuclease (Figure 8). These data are consistent
with a recent publication that demonstrated the ribonu-
clease activity of a VapD homologue from Helicobacter
pylori [35]. Figure 8 shows a RNase activity assay con-
ducted over time using the RNaseAlert (Integrated DNA
Technologies, Coralville, IA) substrate with increasing
amounts of VapD protein. The single-stranded RNA
substrate has a quencher on one end and a fluorophore
(FAM) on the other, and fluoresces brightly when clea-
ved. We included protein elution buffer, purified Cat
(chloramphenicol acetyltransferase), and antitoxin VapXTable 1 Inflammatory response scores of chinchilla
middle ear sections
Strain Inflammatory scorea
1+ 2+ 3+ 4+
86-028NP 1 2 4 1
ΔvapBC-1 1 6 1 0
ΔvapXD 2 4 2 0
ΔvapBC-1 ΔvapXD 4 4 0 0
a8 middle ears were scored for each challenge strain.proteins as negative controls, which were overexpressed
and purified in the identical fashion as VapD. The VapD
protein displayed concentration-dependent RNase acti-
vity over time in this assay.Discussion
As classic type II TA partners, VapB-1 and VapC-1 were
previously found to functionally interact in regulating
the ribonuclease activity of NTHi VapC-1 in vitro [30].
Likewise, in another study, the presence of VapX was
required to relieve the cell growth arrest caused by VapD
[29]. Here we demonstrate with a LexA detection system
that both protein pairs also physically interact in vivo.
Based on the TA model hypothesis, these observations
suggest that under favorable conditions, the antitoxins
VapB-1 and VapX bind to and inhibit the toxins VapC-1
and VapD, respectively. During infections of NTHi-
caused otitis media, various stress stimuli such as nutri-
ent deprivation, antibiotics, and reactive oxygen species
encountered by the organisms might result in the release
of the VapC-1 and VapD toxins from their degraded
or inactivated cognate antitoxins VapB-1 and VapX, res-
pectively. The mobilization of these toxins could then
trigger or facilitate downstream events such as mRNA
decay of metabolism-related transcripts, driving the bac-
terial population into a stasis state and leading to a per-
sistent infection of NTHi in the middle ear of the host.
Deletions of either or both of the vapBC-1 and vapXD
TA loci did not change the cellular morphology of the
organism during co-culture as revealed by TEM exa-
mination, and the ability of the mutants to replicate
normally in rich media was not affected. This indicates
that the observed attenuation of persistence was not
associated with detrimental changes in the morphologic
structure or replication dynamics of the pathogen, but
rather was attributable to the lack of the apparently pro-
tective effect of the vap pairs.
Figure 8 RNase activity assays with purified VapD, Cat, and VapX. Ribonuclease activity over time of the protein elution buffer control (blue),
0.2 μg (red), 0.4 μg (green), and 0.6 μg (purple) of purified VapD, 0.6 μg of chloramphenicol acetyltransferase (Cat, turquoise), or 0.6 μg of VapX
(orange) assayed with the RNaseAlert test kit (IDT, Coralville, IA). Indicated amounts of proteins were added to 25 pmol fluorophore-conjugated
RNaseAlert substrate. The substrate has a quencher on one end and a fluorophore (FAM) on the other. Cleavage of the single-stranded RNA
removed the quencher and the resulting fluorescence was read on a MiniOpticon real-time detection system. The Cat protein and the VapX
antitoxin were overexpressed and purified in an identical fashion to VapD and serve as negative protein controls.
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zyme activity that switches bacterial cells over to meta-
bolic stasis under stressful conditions such as starvation
[36,37] as well as heat, osmotic and free radical-induced
stress [38]. Indeed, VapC toxin homologues from M.
tuberculosis inhibited growth when expressed without
their cognate VapB antitoxins in M. smegmatis [39]. An
obvious conclusion to be drawn from this conserved at-
tribute is that, without the toxin present to facilitate a
state of bacteriostasis, the organism could continue to
replicate under conditions that would normally allow
toxin activation followed by growth arrest. Our data sug-
gest that the loss of the ability to modulate replication is
detrimental to NTHi in our infection models. For ex-
ample, the ΔvapBC-1 mutant co-cultured with EpiAir-
way tissues displayed a marked attenuation of survival,
suggesting that the vapBC-1 locus contributed signifi-
cantly to persistence under these conditions. Deletion of
the vapXD locus or both vapBC-1 vapXD loci reduced
NTHi persistence to similar levels when co-cultured
with the EpiAirway tissues, indicating that the vapXD
locus was also involved in maintaining the NTHi sur-
vival during extended infections. Interestingly, during
the early (Day 1) and late (Day 8) time points, the differ-
ences between the wild type and mutant strains were
less marked than during Days 2, 4, and 6. The reasons for
this phenotype are unclear, but it may be due to unregu-
lated replication of the vap mutants within the EpiAirway
tissues, which could result in nutrient deprivation-induced
death after the first 24 hours of infection. We have re-
cently shown by TEM and immunoelectron microscopy
that NTHi are often located between the basal cells in
these tissues [40]. While the apical surfaces of infected tis-
sues were undamaged, the basal cells displayed wider
intercellular junctions and pockets of necrotic debris. Thisis consistent with the hypothesis that the late (Day 8)
increases in mutant survival could be due to necrosis of a
subset of basal respiratory epithelial cells, providing more
nutrients to the vap mutants and allowing their numbers
to approach that of the wild type strain.
Our in vivo results further confirmed the EpiAirway
findings by showing that the survival of all three
mutants was significantly decreased when compared to
the wild type strain after a 4-day infection in the chin-
chilla model of otitis media. The double deletion of
vapBC-1 and vapXD did not increase the average at-
tenuation of persistence in comparison to the single de-
letion of vapXD in either model. This lack of synergy
suggests that neither locus serves as an agonist or antag-
onist for the other, but rather that each may act inde-
pendently to modulate replication. Moreover, consistent
with the numbers of viable bacteria recovered, the in-
flammatory scores of the middle ear sections were lower
for the mutants than for the wild type strain, although
the animals were able to mount an effective inflamma-
tory response after infection.
Similar to our VapC-1 data [30], we show that NTHi
VapD displays ribonuclease activity in vitro. This finding
suggests that the toxins of both vap operons may play
key roles in stress-induced post-transcriptional regulation
of gene expression via the mechanism of mRNA cleavage.
Taken together, our in vitro and in vivo data demonstrate
that both the vapBC-1 and vapXD TA loci function to
maintain NTHi survival and virulence. This is the first re-
port, to our knowledge, of the vapBC-1 and vapXD loci
playing a role in the pathogenesis of NTHi infections
in vivo. Other conserved TA pairs have been suggested as
novel antimicrobial targets [41], and our data support the
notion that TA deletion results in detrimental effects on
NTHi infection progression. Further studies are proposed
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toxin activity in vivo.Conclusions
We conclude that the vapBC-1 and vapXD TA loci en-
hance NTHi survival and virulence during infection
in vitro and in vivo using a mechanism of mRNA cleav-
age, and that these conserved TA pairs represent new
targets for the prophylaxis and therapy of otitis media
and other NTHi-caused mucosal diseases.Methods
Bacterial strains and culture conditions
The bacterial strains and plasmids used in these studies
are listed in Table 2. Escherichia coli strains were grown
in LB broth or agar with or without 30 μg/ml kana-
mycin, 100 μg/ml ampicillin, 20 μg/ml chloramphenicol,
or 12 μg/ml tetracycline as required. For the protein-
protein interaction studies, strain SU202 carrying both
pSR658 and pSR659 (unfused control plasmids) or anyTable 2 Bacteria and plasmids used in this study
Strain Description
86-028NP NTHi nasopharyngeal isolate from a pe
BL21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS λ DE3 = λ sBamHI




pUC4K Source of the kanamyc
pBluescript II Cloning vecto
pUCΔEcat Source of the chloramphe
pET24b Expression vec
pSR658 LexA DBD fusion
pSR659 LexA DBD fusion
pDD689 pET24b with the ca
pDD731 pGEM5 with the vapBC-1
pDD788 pBluescript II SK(+) with the
pDD791 pET24b with va
pDD859 pSR658 with vapC-1 fused t
pDD866 pSR658 with vapB-1 fused t
pDD867 pSR659 with vapB-1 fused t
pDD868 pSR659 with vapC-1 fused t
pDD882 pSR658 with vapX fused to
pDD883 pSR659 with vapX fused to
pDD884 pSR659 with vapD fused to
pDD885 pSR658 with vapD fused to
pDD902 pET24b with vaof the tested protein fusions was grown overnight in
LB broth containing 1 mM IPTG and then diluted
and grown to log phase in LB containing 1 mM IPTG
prior to β-galactosidase activity assays. NTHi strains were
grown in brain heart infusion broth or agar supplemented
with 10 μg/ml heme-histidine and 10 μg/ml β-NAD
(sBHI). E. coli strain BL21 (DE3) was used to overex-
press epitope-tagged Cat, VapD and VapX for protein
purification prior to use in ribonuclease (RNase) ac-
tivity assays. To construct the NTHi mutants, trans-
formants were selected on chocolate agar plates with
30 μg/ml kanamycin or 2 μg/ml chloramphenicol as
required. NTHi were routinely cultured at 37°C with
5% CO2.
Construction of NTHi mutants
NTHi 86-028NP ΔvapBC-1, ΔvapXD, and ΔvapBC-1
ΔvapXD mutants were constructed by homologous re-
combination using MIV transformation as previously
described [42]. For the ΔvapBC-1 mutant construction,
the vapBC-1 gene region (2558 bp) was amplified fromSource
diatric otitis media patient R. S. Munson, Jr.
o ΔEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Δnin5 Invitrogen




in cassette Lab collection
r Lab collection





gene deletion This work
vapXD deletion This work
pXD This work
o the LexA DBD This work
o the LexA DBD This work
o the LexA DBD This work
o the LexA DBD This work
the LexA DBD This work
the LexA DBD This work
the LexA DBD This work
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primers BCXbaFor (50-GCTTTCTAGACAGGCTAAAT
ATACCG-30) and BCXbaRev (50-GGTCTCTAGAGG-
CATTGTGCGCCAC-30) with engineered XbaI sites
(underlined). The PCR product was cut with the restric-
tion endonuclease XbaI and cloned into pGEM5 cut
with SpeI, resulting in pDD747. This plasmid was then
cut with BamHI and BglII and gel-purified, creating a
564 bp deletion in the 636 bp vapBC-1 operon. A
1,264 bp kanamycin resistance cassette from pUC4K
was ligated into the linearized plasmid, resulting in
pDD748. To construct the 86-028NP vapBC-1 mutant, a
high-fidelity PCR product was amplified from pDD748
with the primers BCXbaFor and BCXbaRev and used in
MIV transformation. The deletion of the vapBC-1 locus
was confirmed by PCR and DNA sequencing.
For the ΔvapXD mutant construction, a three-step
cloning strategy was used. First, an upstream (573 bp)
region of vapXD gene from 86-028NP genomic coordi-
nates 540086–540579 was amplified by high-fidelity PCR
with the primer pair 86vapXSacFor (50-ACAGGAGCTC
AACTACTCCGTAAA-30) and 86vapXXbaRev (50-CCC
GTCTAGATTAATACAGCCTGTT-30). The DNA frag-
ment cut with SacI and XbaI was cloned into pBlue-
script II SK(+) cut with SacI and XbaI, resulting in
pDD778. A downstream (619 bp) region of vapXD gene
from 86-028NP genomic coordinates 541002–541621
was amplified by high-fidelity PCR with the primer pair
86vapDPstFor (50-CGAACTGCAGATTTGCCTAGATA
AGCC-30) and 86vapDKpnrev (50-ATAAGGTACCAG-
CAGCGCTTCACTACC-30). This fragment was cut with
PstI and KpnI was cloned into pDD778 cut with PstI
and KpnI, resulting in pDD786. Then, a 1,348 bp chlor-
amphenicol resistance cassette obtained from pUCΔEcat
was subsequently cloned into pDD786 cut with BamHI
to form pDD788. To construct the 86-028NP ΔvapXD
mutant, a high-fidelity PCR product amplified from
pDD788 with the primers 86vapxSacFor and 86vapDKpn-
Rev was used in MIV transformation as previously des-
cribed [42]. The deletion of vapXD was confirmed by PCR
and DNA sequencing.
To construct the ΔvapBC-1 ΔvapXD double mutant,
the genomic DNA of 86-028NP ΔvapXD was used
to transform the 86-028NP ΔvapBC-1 mutant. The
86-028NP ΔvapBC-1 ΔvapXD double mutant clones
were selected on chocolate agar plates with both kana-
mycin and chloramphenicol. The positive clones were
characterized by PCR for both deletions using the gen-
omic DNAs of the positive candidates as the template,
and verified by DNA sequencing of the amplicons.
Heterodimerization assays
VapB-1 and VapC-1: for these assays, vapB-1 was fused
to either the LexA DNA binding domain (DBD) in thevector pSR658, resulting in pDD866, or to the LexA
DBD of pSR659, resulting in pDD867 [31]. Likewise,
vapC-1 was fused to either the LexA DBD in the vector
pSR659, resulting in pDD868, or to the LexA DBD in
pSR658, resulting in pDD859. Because the copy number
of each plasmid is different, we performed reciprocal
assays in which we switched the protein fusions (i.e.
from the low copy to the high copy plasmid, and vice
versa) as internal controls. Both fused plasmid sets
(pDD866 and pDD868, or pDD867 and pDD859) or the
unfused vectors (pSR658 and pSR659) were co-trans-
formed and co-expressed in the reporter strain SU202.
This strain has a chromosomal construct that consists of
a lacZ reporter gene controlled by the strong sulA
promoter, which contains an engineered LexA operator
sequence. When there is no fusion to the LexA DBD,
the strain constitutively expresses a high level of β-galac-
tosidase. However, if a protein fused to the LexA
DBD in pSR658 and another protein fused to the
LexA DBD in pSR659 can heterodimerize, a compe-
tent LexA dimer is formed that can bind to the engi-
neered LexA operator and repress transcription of
lacZ in the reporter strain SU202. Homodimers, if
formed, cannot bind to the engineered operator site.
Expression of the LexA fusion in pSR658 and pSR659
is induced by IPTG, and since β-galactosidase is a
very stable enzyme, the reporter strain is routinely
grown overnight with IPTG, so that any enzyme
that was transcribed prior to induction of the LexA
chimera has the opportunity to degrade. This strategy
resulted in a more reliable and accurate quantitation of
heterodimerization. Following overnight incubation in LB
broth with 1 mM IPTG, the reporter strain carrying
pSR658 and pSR659, or the LexA DBD fusions, was
diluted and grown to log phase in LB broth with 1 mM
IPTG. The amount of heterodimerization was quantitated
by the repression of lacZ activity as indicated by β-
galactosidase activity assays and compared to the activity
of the reporter strain carrying pSR658 plus pSR659 (no fu-
sion). The algorithm for determining β-galactosidase activ-
ity is: [OD420-(1.75*OD550)/t*v*OD600]*1000, where t=time
of reaction development in minutes, v=volume of sample
in milliliters, and OD600 is the optical density of the cul-
ture at 600 nm [43]. This equation allows normalization of
different culture densities for comparison purposes.
VapX and VapD: for these assays, vapX was fused to
the LexA DBD in pSR658, resulting in pDD882, and to
the LexA DBD in pSR659, resulting in pDD883. Like-
wise, vapD was fused to the LexA DBD in pSR659,
resulting in pDD884, and the LexA DBD in pSR658,
resulting in pDD885. Heterodimerization assays measu-
ring β-galactosidase activity were carried out and quanti-
tated as above. Each pair was analyzed at least three
times in triplicate.
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To perform ribonuclease (RNase) activity assays, the cat
(chloramphenicol acetyltransferase) gene was PCR-
amplified from pACYC184 by high-fidelity polymerase
and ligated to the SacI/XhoI-cut pET24b expression vec-
tor, resulting in Cat with a C-terminal polyhistidine tag
in pDD689. Similarly, vapXD was amplified from 86-
028NP genomic DNA and ligated to the SacI/XhoI-cut
pET24b expression vector, resulting in VapD with a C-
terminal polyhistidine tag in pDD791. Finally, vapX was
amplified from 86-028NP genomic DNA and ligated to
the SacI/XhoI-cut pET24b expression vector, resulting in
VapX with a C-terminal polyhistidine tag in pDD902. To
overexpress each protein for purification, pDD689,
pDD791, and pDD902 were grown to logarithmic phase
in BL21(DE3) and induced for 3 hours with 1 mM IPTG.
Protein isolation from induced cells was performed with
the MagneHis protein purification system (Promega,
Madison, WI USA) according to the manufacturer’s
instructions.
NTHi growth dynamics
To compare growth dynamics, the 86-028NP wild type
strain and the ΔvapBC-1, ΔvapXD, and ΔvapBC-1
ΔvapXD mutants were re-suspended from chocolate
agar plates grown for 18 hours at 37°C in 5% CO2 into
fresh sBHI broth to an OD600 of ~0.1, then 200 microli-
ters of each re-suspension was placed in triplicate into a
sterile nontreated flat-bottomed 96 well plate (#351172,
BD Biosciences, Bedford, MA, USA). Empty wells were
filled with 200 microliters of sterile water to decrease
evaporation, and the plate was covered with sterile gas
permeable sealing film (#9123-6100, USA Scientific,
Ocala, FL, USA). The plate was incubated for 11 hours
with shaking at 35°C in a Multiskan FC spectrophotom-
eter (ThermoFisher Scientific, Waltham, MA, USA), and
the OD595 was read hourly. Two biological replicates
and three technical replicates were performed and ana-
lyzed by one-way analysis of variance (ANOVA) for in-
dependent samples.
Transmission electron microscopy (TEM) of NTHi strains
co-cultured with EpiAirway tissues
Primary human respiratory epithelial tissues grown at
the ALI, the EpiAirway model (MatTek #AIR-100-ABF,
Ashland, MA USA) was used for co-culture with NTHi
[32]. Each 0.6 cm2 tissue was fed basally by 1 ml of the
proprietary antibiotic-free maintenance medium, AIR-
100-MM-ABF (MM) and cultured at 37°C with 5% CO2.
Each insert was washed daily with 200 μl of pre-warmed
Dulbecco’s PBS (D-PBS) with calcium and magnesium
and the basal MM was renewed daily. NTHi strains were
grown overnight on chocolate agar plates at 37°C with
5% CO2. Bacteria were then suspended in D-PBS to anOD600 of ~0.2, and diluted to the desired inoculum. The
tissues were inoculated apically with ~1.0 × 107 colony
forming units (CFU) in ~25 microliters per insert with
the 86-028NP parent strain or the ΔvapBC-1, ΔvapXD,
and ΔvapBC-1 ΔvapXD mutants. On day 5 after infec-
tion, the tissues were fixed with 1.25% glutaraldehyde
and 2.0% paraformaldehyde in 100 mM sodium cacody-
late buffer (pH 7.2) for 24 hours. The membranes were
then removed from the plastic inserts using a #11
pointed scalpel blade, processed by the Georgia Health
Sciences University Electron Microscopy Core for TEM
and imaged with a JEOL JEM 1230 transmission elec-
tron microscope (JEOL, Peabody, MA USA) to identify
the morphology of the bacteria.
Quantitation of NTHi inside infected EpiAirway tissues
The EpiAirway tissues at the ALI (#AIR-100-ABF,
MatTek, Ashland, MA USA) were infected apically with
the suspensions of either the 86-028NP parent strain,
or the ΔvapBC-1, ΔvapXD, and ΔvapBC-1 ΔvapXD
mutants individually at ~107 CFU per insert (n = 6). The
inoculation suspensions were quantified by dilution and
plating for viable colony counting. The inserts were
washed and the basal MM renewed daily. On day 1, 2, 4,
6 and 8 after infection, each insert was harvested as pre-
viously described [32]. Briefly, each insert was washed
with D-PBS, then 300 μl of MM with gentamicin
(100 μg/ml) was added apically to each insert, with 1 ml
of MM with gentamicin (100 μg/ml) added basally. After
1 h of incubation at 37°C with 5% CO2, the inserts were
washed 3X with D-PBS without calcium and magne-
sium, and 250 μl of 1% saponin in D-PBS without cal-
cium and magnesium was added apically to each insert
and incubated at 37°C for 10 min. Subsequently, the tis-
sues were harvested, disaggregated and diluted to 1 ml
in D-PBS. The suspensions were then diluted serially
and plated onto chocolate agar plates for bacterial CFU
counts.
NTHi survival in the chinchilla otitis media model
Healthy female adult (400–600 g) chinchillas were pur-
chased from a commercial supplier and handled in ac-
cordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Mercer University Institutional Animal Care and Use
Committee (Assurance Number: A3725-01). All surgery
was performed under isoflurane anesthesia, and all ef-
forts were made to minimize suffering. Animals were al-
lowed to acclimate to the vivarium for 1 week prior to
challenge, and none had any visible signs of middle ear
infection as detected by otoscopy. The 86-028NP parent
strain and the ΔvapBC-1, ΔvapXD, and ΔvapBC-1
ΔvapXD mutants were recovered from frozen stocks
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CO2. The bacteria were harvested, suspended in D-PBS
containing 0.1% gelatin (D-PBSG), loaded into tubercu-
lin syringes, and maintained on ice for the challenges.
Chinchillas were anesthetized by isoflurane inhalation
and each middle ear was injected transbullarly with
100 μl (~ 1000 CFU) of bacteria (n = 4 to 5 animals with
8 to 10 middle ears per challenge strain) or D-PBSG
alone (control). Actual challenge doses were confirmed
by plating followed by colony counting. On day 4 post-
challenge, the animals were euthanized by cardiac exsan-
guination and their superior bullae were opened. Middle
ear fluid was recovered, and each middle ear was washed
with 1.0 ml of D-PBSG. An aliquot of each middle ear
wash was diluted serially and plated on chocolate agar
for CFU counts. Additionally, each mutant strain reco-
vered was plated initially on chocolate agar with and
without its cognate antibiotic marker to determine if any
genetic changes had occurred during middle ear chal-
lenge. No significant differences between the numbers of
colonies recovered on plates with or without antibiotics
were observed (data not shown).
Histology of chinchilla bullae
Following sacrifice, the chinchilla ears were dissected,
fixed with 10% neutral buffered formalin, and decalcified
with 5% formic acid. Each ear was cut at the midline in
the sagittal plane, and both halves were processed and pa-
raffin-embedded. Step sections of the distal halves were
performed and the resulting slides were stained with
hematoxylin-eosin (H&E) for analysis. One of us (A.N.W.),
a Board-certified pathologist, scored randomized and
blinded sections from the same step-sections of each ear
for the relative level of the inflammatory response, with the
control (buffer only) ears being scored as 0 (no inflamma-
tion), with the most inflammation being designated as 4+.
Ribonuclease (RNase) activity assays
Varying amounts of purified VapD, VapX, or Cat (chlor-
amphenicol acetyltransferase) proteins were incubated
at 37°C for 30 minutes with 25 pmol of RNaseAlert
substrate (Integrated DNA Technologies, Coralville, IA)
using the manufacturer’s buffer in a final volume of 25 μl.
The RNaseAlert substrate is a single stranded RNA with a
fluorophore (FAM) on one end and a quencher on the
other. When cleaved, the substrate fluoresces brightly.
This sensitive assay allows us to monitor RNase activity in
real time. Negative controls consisted of the MagneHis
protein elution buffer with no protein, and 0.6 μg of the
Cat and VapX proteins. The reactions were placed in a
Bio-Rad white 48-well PCR plate, covered with optical film
and incubated in a MiniOpticon thermocycler at 37°C.
Plate reads were taken every 5 minutes for 30 minutes.
The average relative fluorescence units (RFU) from twoindependent assays are reported. All solutions used were
nuclease free or treated with diethyl pyrocarbonate.
Statistical analysis
Data are presented as the mean ± standard deviation
(SD). Differences among multi-group treatments were
determined by one-way ANOVA using the VassarStats
website for statistical computation (http://faculty.vassar.
edu/lowry/VassarStats.html). P values of ≤0.05 were con-
sidered significant, with significant differences further
analyzed using a Tukey HSD post hoc test.
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